CD38, Plasma Cell, Thymocyte, T_Cell activated, gp45, Clone CLB_1D5, Mab anti_Human
- Known as:
- CD38, Plasma Cell, Thymocyte, T_Cell activated, gp45, Clone CLB_1D5, Mab anti_Human
- Catalog number:
- CLBM1642
- Product Quantity:
- 1 ml.
- Category:
- -
- Supplier:
- Accu
- Gene target:
- CD38 Plasma Cell Thymocyte T_Cell activated gp45 Clone CLB_1D5 Mab anti_Human
Related genes to: CD38, Plasma Cell, Thymocyte, T_Cell activated, gp45, Clone CLB_1D5, Mab anti_Human
- Gene:
- CD38 NIH gene
- Name:
- CD38 molecule
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 4p15.32
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2014-11-18
Related products to: CD38, Plasma Cell, Thymocyte, T_Cell activated, gp45, Clone CLB_1D5, Mab anti_Human
Related articles to: CD38, Plasma Cell, Thymocyte, T_Cell activated, gp45, Clone CLB_1D5, Mab anti_Human
- ADORA2A (adenosine A2a receptor) and ADORA2B propagate immunoregulatory signals, including restricting both innate and adaptive immunity, though recent data also suggest a tumor suppressor effect in certain settings. We evaluated the RNA expression from 514 tumors in a clinical-grade laboratory; 489 patients with advanced/metastatic disease had clinical outcome correlates. Transcript expression was standardized to internal housekeeping genes and ranked (0-100 scale) relative to 735 specimens from 35 different cancer types. Transcript abundance rank values were defined as "low/moderate" (0-74) or "high" (75-100) percentile RNA expression ranks. Overall, 20.8% of tumors had high ADORA2A (≥75 percentile RNA rank). The greatest proportion of high ADORA2A expressors was found in neuroendocrine and breast cancers and sarcomas, whereas the lowest was found in colorectal and ovarian cancers, albeit with patient-to-patient variability. In multivariable logistic regression analysis, there was a significant positive correlation between high ADORA2A RNA expression and a high expression of the immune checkpoint-related molecules PD-1 ( = 0.015), VISTA ( ≤ 0.001), CD38 ( = 0.031), and CD39 ( ≤ 0.001). In 217 immunotherapy-treated patients, high ADORA2A did not correlate significantly with progression-free ( = 0.51) or overall survival (OS) ( = 0.09) from the initiation of the checkpoint blockade. However, high versus not-high ADORA2A transcript expression correlated with longer OS from the time of advanced/metastatic disease (N = 489 patients; (HR 0.69 (95% CI 0.51-0.95) ( = 0.02)). Therefore, high ADORA2A transcript levels may be a favorable prognostic factor, unrelated to immunotherapy. Importantly, ascertaining co-expression patterns of ADORA2A with PD-1 and VISTA in individual tumors as a basis for the precision co-targeting of ADORA2A and these other checkpoint-related molecules warrants investigation in clinical trials. - Source: PubMed
Publication date: 2024/04/26
Shreenivas AdityaNishizaki DaisukeLee SuzannaPabla SarabjotNesline MaryConroy Jeffrey MDePietro PaulKato ShumeiKurzrock Razelle - Multiple myeloma is a malignancy characterized by the accumulation of malignant plasma cells in bone marrow and the production of monoclonal immunoglobulin. A hallmark of cancer is the evasion of immune surveillance. Histone deacetylase inhibitors have been shown to promote the expression of silenced molecules and hold potential to increase the anti-MM efficacy of immunotherapy. The aim of the present work was to assess the potential effect of tinostamustine (EDO-S101), a first-in-class alkylating deacetylase inhibitor, in combination with daratumumab, an anti-CD38 monoclonal antibody (mAb), through different preclinical studies. Tinostamustine increases CD38 expression in myeloma cell lines, an effect that occurs in parallel with an increment in CD38 histone H3 acetylation levels. Also, the expression of MICA and MICB, ligands for the NK cell activating receptor NKG2D, augments after tinostamustine treatment in myeloma cell lines and primary myeloma cells. Pretreatment of myeloma cell lines with tinostamustine increased the sensitivity of these cells to daratumumab through its different cytotoxic mechanisms, and the combination of these two drugs showed a higher anti-myeloma effect than individual treatments in ex vivo cultures of myeloma patients' samples. In vivo data confirmed that tinostamustine pretreatment followed by daratumumab administration significantly delayed tumor growth and improved the survival of mice compared to individual treatments. In summary, our results suggest that tinostamustine could be a potential candidate to improve the efficacy of anti-CD38 mAbs. - Source: PubMed
Publication date: 2024/04/26
Díaz-Tejedor AndreaRodríguez-Ubreva JavierCiudad LauraLorenzo-Mohamed MauroGonzález-Rodríguez MartaCastellanos BárbaraSotolongo-Ravelo JanetSan-Segundo LauraCorchete Luis AGonzález-Méndez LorenaMartín-Sánchez MontserratMateos María-VictoriaOcio Enrique MGarayoa MercedesPaíno Teresa - The decline in female fecundity is linked to advancing chronological age. The ovarian reserve diminishes in quantity and quality as women age, impacting reproductive efficiency and the aging process in the rest of the body. NAD is an essential coenzyme in cellular energy production, metabolism, cell signaling, and survival. It is involved in aging and is linked to various age-related conditions. Hallmarks associated with aging, diseases, and metabolic dysfunctions can significantly affect fertility by disturbing the delicate relationship between energy metabolism and female reproduction. Enzymes such as sirtuins, PARPs, and CD38 play essential roles in NAD biology, which actively consume NAD in their enzymatic activities. In recent years, NAD has gained much attention for its role in aging and age-related diseases like cancer, Alzheimer's, cardiovascular diseases, and neurodegenerative disorders, highlighting its involvement in various pathophysiological processes. However, its impact on female reproduction is not well understood. This review aims to bridge this knowledge gap by comprehensively exploring the complex interplay between NAD biology and female reproductive aging and providing valuable information that could help develop plans to improve women's reproductive health and prevent fertility issues. - Source: PubMed
Publication date: 2024/04/25
Ahmed MehboobRiaz UmairLv HaimiaoYang Liguo - People living with HIV (PLWH) with multidrug-resistant (MDR) viruses have limited therapeutic options and present challenges regarding clinical management. Recent studies have shown that passive transfer of combination broadly neutralizing antibodies (bNAbs) against HIV and anti-domain 1 CD4 antibody UB-421 can sustain virologic suppression in PLWH in the absence of antiretroviral therapy (ART). Yet studies addressing the therapeutic potential of these antibodies and/or detailed characterization of immunologic and virologic parameters in PLWH with MDR HIV are lacking. - Source: PubMed
Publication date: 2024/05/09
Rai M AliBlazkova JanaJustement Jesse SShi VictoriaKennedy Brooke DManning Maegan RMcLaughlin MarySneller Michael CPau Alice KMoir SusanChun Tae-Wook - In most cases, Zika virus (ZIKV) causes a self-limited acute illness in adults, characterized by mild clinical symptoms that resolve within a few days. Immune responses, both innate and adaptive, play a central role in controlling and eliminating virus-infected cells during the early stages of infection. - Source: PubMed
Publication date: 2024/05/09
Samri AssiaBandeira Antonio CarlosGois Luana LeandroSilva Carlos Gustavo RegisRousseau AliceCorneau AurelienTarantino NadineMaucourant ChristopherQueiroz Gabriel Andrade NonatoVieillard VincentYssel HansCampos Gubio SoaresSardi SilviaAutran BrigitteRios Grassi Maria Fernanda